Adult Cystic Fibrosis Program at Massachusetts General Hospital

Adult Cystic Fibrosis Program at Massachusetts General Hospital This is a for patients to share with other patients and for providers to post important information.

12/09/2022

Important message from Vertex.....Happy Friday! Knowing the holidays can be a stressful time, please let your patients know that Vertex will have interruptions in their shipping schedule during the holiday season. These changes may impact pharmacy availability. To avoid any potential treatment interruptions this may cause, please encourage your patients to refill ahead of the 12/22 Vertex shipping cut off.
We will have a team available at GPS during regular hours throughout the holiday season.
Please see the holiday Vertex shipping schedule below:
Christmas Holiday Shipment & Order Schedule:
All orders received after 5pm CST on Thursday 12/22 will not be processed for shipping until Tuesday 12/27.

All orders received after 5pm CST on Thursday 12/29 will not be processed for shipping until Tuesday 1/3.

No orders will be shipped 12/23-12/26 nor 12/30-1/2

If you have any questions, please reach out.
Lindsay

03/13/2020

The Cystic Fibrosis Foundation has prepared FAQs to address key concerns we have heard from the CF community regarding the coronavirus (COVID-19) outbreak, including information from the CDC on the risk to people with underlying health conditions and steps you can take to protect yourself and your l...

08/28/2017

Centurion Labs Issues Voluntary Nationwide Recall of Ninjacof (Lot # 200N1601) and Ninjacof A (Lot # 201NA1601) Products Due to Potential Burkholderia Cepacia Contamination

Announcement
Centurion Labs is voluntarily recalling, as a precautionary measure, 1 lot of Ninjacof (Lot # 200N1601) and 1 lot of Ninjacof A (Lot # 201NA1601) manufactured by Vilvet (Dania Beach, FL) and distributed by Centurion Labs to the retail level due to potential contamination with Burkholderia cepacia. Centurion was notified by the FDA regarding the potential contamination as they discovered this product may have been manufactured in a Pharmatech, FDA registered facility, in Davie, FL. that was found to have a product that contained B. cepacia.

Use of a product that may contain B. cepacia, could result in infections in patients with compromised immune systems and in patients with chronic lung conditions such as cystic fibrosis. Some of these infections may be serious or even life threatening in the at-risk patient population.

Ninjacof and Ninjacof A are used to temporarily relieve symptoms due to the common cold, allergic rhinitis or other respiratory allergies and the products are sold in 473 mL bottles with the expiration date of 11/2018. The affected products are Ninjacof with Lot # 200N1601 (NDC 23359-032-16) and Ninjacof A with Lot # 201NA1601 (NDC 23359-033-16) and both were distributed within the following states: Alabama, Arkansas, Florida, Georgia, Louisiana, Missouri, Mississippi, New Jersey, North Carolina, Ohio, Oklahoma, South Carolina, Tennessee, and Texas.

Centurion Labs is notifying its distributors and customers by recall letter. To date Centurion Labs has not found any B. cepacia or received any complaints for the products or lots listed. However, it is recommended that patients, pharmacies, and healthcare facilities that have the recalled product on hand stop their use immediately.

Consumers with questions regarding this recall can contact the company at Centurion Customer Support: recall@centurionlabs.com or 601-852-3681 (M-F 8am – 5pm Central Standard Time).

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
•Complete and submit the report Online: www.fda.gov/medwatch/report.htm
•Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

08/10/2017

Voluntary Nationwide Recall of all Liquid Products Manufactured by Pharmatech LLC and Distributed by Leader Brand, Major Pharmaceuticals, and Rugby Laboratories Due to Possible Product Contamination

For Immediate Release
August 10, 2017
Contact
Consumers
Rugby Laboratories/Major Pharmaceuticals Customer Support
 1-800-645-2158

Media
Corey Kerr
 (614) 757-3383

Announcement

As a precautionary measure, the distribution firms Leader Brand, Major Pharmaceuticals, and Rugby Laboratories are jointly issuing a nationwide voluntary recall of all lots within expiry of all liquid products manufactured by PharmaTech LLC at its FDA registered facility in Davie, Fla. due to possible product contamination.

The distribution firms are committed to patient safety and are partnering with the Food and Drug Administration to notify customers who may be in possession of liquid products manufactured by PharmaTech LLC. Please see the below list of affected products.

The products subject to this recall were distributed nationwide to wholesale and retail facilities, including hospitals and pharmacies. Through recent communication with FDA, the distribution firm Rugby Laboratories learned of a potential issue with a product manufactured by PharmaTech LLC. The FDA informed Rugby Laboratories that it received several adverse event reports of B. cepacia infections in patients, which may be linked to PharmaTech LLC manufactured Diocto Syrup or Diocto Liquid (docusate sodium solutions). In response, Rugby Laboratories issued a voluntary recall on August 3, 2017, of the PharmaTech LLC manufactured Diocto Syrup and Diocto Liquid. As a precautionary measure based on additional information received from the FDA, the three distribution firms are recalling all lots within expiry of all liquid products manufactured by PharmaTech LLC.

The distribution firms are notifying their distributors and customers by recall letter and are arranging for return of all recalled products. Consumers, pharmacies, and healthcare facilities that have product being recalled should stop using and dispensing the product immediately.

Consumers with questions regarding this recall should contact Rugby Laboratories/Major Pharmaceuticals Customer Support at 1-800-645-2158, available Monday through Friday 8 a.m. – 8 p.m. EST or Leader Customer Support at 1-800-200-6313 option #1 Monday through Thursday 8 a.m. – 7p.m. and Friday 8 a.m. – 5 p.m EST. Consumers can contact their physician or healthcare provider if they have additional questions about this product.

Adverse reactions or quality problems experienced with the use of these products may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax:
•Complete and submit the report Online: www.fda.gov/medwatch/report.htm
•Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the full knowledge of the U.S. Food and Drug Administration.

LEADER BRAND
Liquid Multivitamin Supplement for Infants and Toddlers 50 mL, UPC: 096295128611 ALL LOTS
Liquid Vitamin D Supplement for Breastfed Infants 400 IU 50 mL, UPC: 096295128628 ALL LOTS

MAJOR PHARMACEUTICALS
Certa-Vite Liquid 236ML 00904-5023-09 ALL LOTS
Poly-Vita Drops 50ML 00904-5099-50 ALL LOTS
Poly-Vita Drops W/Iron 50ML 00904-5100-50; ALL LOTS
Ferrous Drops Iron Supp 50ML 00904-6060-50 ALL LOTS
D-Vita Drops 50ML 00904-6273-50 ALL LOTS
Tri-Vita Drops 50ML 00904-6274-50 ALL LOTS
Senna Syrup 237ML 00904-6289-09 ALL LOTS

RUGBY LABORATORIES
C Liquid 500mg 118ML 00536-0160-97 ALL LOTS
Diocto Liquid 50mg/5ml 473ML 00536-0590-85 ALL LOTS
Ferrous Sulfate Elixir 473ML 00536-0650-85 ALL LOTS
Fer Iron Liquid 50ML 50ML 00536-0710-80 ALL LOTS
Senexon Liquid 237ML 00536-1000-59 ALL LOTS
Diocto Syrup 60MG/15ML 473ML 00536-1001-85 ALL LOTS
Aller Chlor Syrup 120ML 00536-1025-47 ALL LOTS
Calcionate Syrup 16OZ 00536-2770-85 ALL LOTS
Cerovite Liquid 236ML 00536-2790-59 ALL LOTS
D3 400iu Liquid 50ML 00536-8400-80 ALL LOTS
Poly-Vitamin Liquid 50ML 00536-8450-80 ALL LOTS
Tri-Vitamin Liquid 50ML 00536-8501-80 ALL LOTS
Poly-Vitamin W/Iron Liquid 50ML 00536-8530-80 ALL LOTS

04/05/2017

In light of the recent Epi-Pen recall, Allergy Associates at Massachusetts General Hospital is committed to providing patients accurate information and assistance to identify if their Epi-Pen device was recalled and needs to be replaced. Read more: http://www.massgeneral.org/allergy/patiented/epipen.aspx

Allergy Associates at Massachusetts General Hospital is committed to providing our patients with accurate information and assistance regarding the Epi-Pen recall.

Dear CF Foundation Staff, As you may have heard, the group currently known as the Cystic Fibrosis Adult and Family Advis...
04/05/2017

Dear CF Foundation Staff,

As you may have heard, the group currently known as the Cystic Fibrosis Adult and Family Advisors group (AFA) is changing its name to Community Voice, a name chosen by the CF community to more accurately embody the contributions of this group. This change will go into effect on April 8th.

Community Voice is the Foundation’s way to ensure that the diverse perspectives of the CF community, including individuals with CF and their family members, are being heard and used to drive improvements in Foundation initiatives.

This collective is our go-to group for projects and initiatives happening at the national level, including innovations in CF care, public policy and advocacy, drug development and research, and programs for people with CF and their families.

Participation in these projects ranges from brief surveys, to focus groups, to serving on a committee. Members choose their level of involvement based on their interests and schedule.

If you have a project that would benefit from input CF community input, please contact Megan Bradley at mbradley@cff.org. To learn more about this group, visit CFF.org/CommunityVoice.

We look forward to working with you to identify continued opportunities for engagement with the CF community.

Community Voice provides opportunities for people with cystic fibrosis and their family members to have an active say in Cystic Fibrosis Foundation initiatives, ensuring the voice of the cystic fibrosis community is helping drive improvements that will benefit everyone affected by CF.

03/08/2017

The CF community voice is needed! Stay up-to-date using
the new section on cff.org about health reform.




To: Care Center Staff

From: Mary Dwight and Bruce Marshall

Re: An update on health care reform

Date: March 8, 2017

Dear Colleagues,

As many of you may know, House Republicans released the first drafts of their plans to repeal and replace the Affordable Care Act this week. The CF Foundation's analysis reveals the bills from the Energy & Commerce and Ways & Means Committees will significantly reduce coverage and consumer protections for people with CF.

The Cystic Fibrosis Foundation has been engaged with House members and staff throughout this process making the needs of the community known. Earlier this week, we signed on with ten other high-profile patient organizations, signaling our core principles that health insurance should be affordable, accessible, and adequate. These principles align with those set forth by the CF Foundation and form the lens through which we will evaluate all related legislation.

The draft bills will be reviewed by several committees (aka "a markup") before they are slated to be voted on by the full House of Representatives in a couple of weeks. In advance of the first committee hearings on Wednesday, March 8th, CFF issued a statement (see below) outlining our concerns and commenting on how the bills will impact people with cystic fibrosis. Following the mark ups, the Foundation will evaluate any changes made to the bills and will consider issuing a more detailed letter to House leadership.

Of note, House Republicans must operate within the parameters of a budget resolution passed in January, thereby limiting which provisions of the Affordable Care Act they can change. In other words, the current bills cannot change non-budget related policies such as protections for pre-existing conditions, allowing dependent coverage, and eliminating lifetime and annual caps.

The CF community voice is stronger than ever. Just last week we held nearly 300 meetings with Congressional offices to discuss health care issues. We continue to need your voice. Next week the community at large will be asked to participate in a broad advocacy campaign to email and call their representatives in Congress. We hope you will join us to carry this message forward to your elected officials.

Please continue to stay up-to-date using the new section on cff.org about health reform. If you have additional questions, please contact Zoe Aldrich at zaldrich@cff.org.

We will continue to keep you posted.

Thank you for all you do for people with CF,
Mary and Bruce


Mary B. Dwight
Senior Vice President for Policy & Patient Assistance Programs
Cystic Fibrosis Foundation | National Office
mdwight@cff.org
301-841-2639



Bruce C. Marshall, M.D., M.M.M.
Senior Vice President of Clinical Affairs
Cystic Fibrosis Foundation | National Office

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

FOR IMMEDIATE RELEASE
March 7, 2017


Cystic Fibrosis Foundation Issues Statement on House Health Reform Bills

(Bethesda, MD) - The Cystic Fibrosis Foundation issued the following statement in response to the bills released by the House Energy and Commerce Committee and the House Committee on Ways and Means.

"The bills released by the two House committees this week fail to adequately protect people living with cystic fibrosis and place the lives of millions of Americans living with serious and chronic diseases at risk.

The CF community has come so far in the fight against this deadly disease, and it's crucial that this progress is not jeopardized by inadequate, unaffordable health care coverage. At a time when advances in CF care are more promising than ever, these measures could restrict our community's access to existing therapies as well as new treatments as they become available.

In particular, we are concerned that:
• The legislation would effectively eliminate Medicaid expansion and alter its financing structure in a way that would put coverage of new and innovative treatments at risk. Medicaid provides a critical source of health care coverage for 50 percent of children and one-third of adults with CF. We must preserve this safety net by retaining expanded eligibility and ensuring adequate funding for Medicaid.
• The bills do not support an individual market that works well for people with intensive health care needs, including people with CF. By providing states with funds that could be used for a wide range of activities-including high risk pools, reinsurance, provider payments, and programs to promote access to preventive services-these bills offer no assurance that people with CF will be able to purchase an adequate, affordable plan in the individual insurance market, regardless of their state.
• The legislation inadequately supports young people with high health care needs, by basing financial assistance primarily on age rather than income. This could leave younger individuals with CF without enough support to purchase a plan that covers the breadth of their specialty care. This is particularly important for our community, as 75 percent of people with CF are under the age of 30.

We commend lawmakers for not exposing patients to higher premiums based on their health care status when they have a gap in coverage, as was put forward in other proposals. On behalf of the CF community, we urge members of Congress to protect and address the needs of people with cystic fibrosis, a life-threatening disease. We look forward to working with members of Congress as they continue to refine this legislation and will evaluate any bills through the lens of our policy principles."

07/28/2016

Use the Cystic Fibrosis Foundation Clinical Trial Finder to find enrolling studies for people with CF. Search by location, age, mutation and more.

Please support this wonderful young woman who is the daughter of my best friend and like a daughter to me!
02/17/2016

Please support this wonderful young woman who is the daughter of my best friend and like a daughter to me!

Dear Family and Friends, As many of you know, I have been selected to run in the 2016 Boston Marathon with the MGH Cystic Fibrosis Team. I am so honored and excited to be given this opportunity! Several years ago, I started a weight loss journey and running quickly became a central part of it and my…

01/29/2016

August Engelhardt believed coconuts were a nutritional and spiritual panacea. So in 1902, he sailed to the South Pacific to start a utopian cult that survived only on the fruit. It ended calamitously.

01/28/2016

Learn more about how this 8 years old boy with cystic fibrosis is improving his lung function.

01/16/2016

My five favorite accounts on Instagram capture the spirit, strength and perseverance of the CF community online.

Address

50 Staniford St, Ste 801
Boston, MA
02114

Website

Alerts

Be the first to know and let us send you an email when Adult Cystic Fibrosis Program at Massachusetts General Hospital posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Adult Cystic Fibrosis Program at Massachusetts General Hospital:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category